CMS Entry id: 2710 | Channel: News landing page | Template: news/index

Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin


28 July 2022

CANTAB to be used in US Department of Defense PTSD trial

We are pleased to announce two agreements in a new therapeutic area for Cambridge Cognition, post-traumatic stress disorder ("PTSD").  Most recently, a research agreement was entered into with the United States Department of Defense, following on from a contract secured earlier this year with a top 10 pharmaceutical company.  

18 July 2022

Join us at AAIC 2022

We are looking forward to attending this year’s Alzheimer’s Association International Conference (AAIC) in San Diego from 31st July to 4th August and learning about the latest developments in dementia research.

14 July 2022

2022 CANTAB Research Grant winners announced

It has been another highly competitive year for our CANTABTM Research Grant, with the large number of high-quality applications making picking just three winners a challenge for our judging panel! Here we reveal the winning grants.

31 May 2022

Cambridge Cognition partners on ambitious project for digital measurement of Alzheimer’s disease and related dementia symptoms

Cambridge Cognition is pleased to announce that they have joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measure Development project. As a partner of this innovative, collaborative effort, Cambridge Cognition will work to harness the potential of digital medicine to advance therapies for ADRD.

13 May 2022

Investigating the Impact of COVID-19 on Cognition

Children of the 90s collaborates with researchers at Cambridge Cognition to investigate the cognitive impacts of COVID-19.

16 December 2021

Electronic Clinical Outcomes Assessment contract win worth over £500,000

Cambridge Cognition is pleased to announce that it has won a contract worth over £500,000 to provide electronic clinical outcome assessments ("eCOA"). 

9 December 2021

Cambridge Cognition wins £1.0m schizophrenia clinical trial contract

Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for an additional schizophrenia clinical trial worth £1.0m.